Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (7214)	3/14/1999 11:09:00 AM
From: Anthony Wong	Respond to of 9523

IMS Health Reports 263,809 U.S. Celebrex Prescriptions Dispensed in First Week of March (Last updated 4:58 PM ET March 12) LONDON (BW HealthWire) - IMS HEALTH (NYSE:RX) today reported that for the week ending Mar. 5, total prescriptions dispensed for Celebrex in the U.S. were an estimated 263,809, up 16 percent from the previous week. Celebrex mail-order prescriptions totaled 13,074 -- a 25 percent rise from the week ending Feb. 26. Searle's Celebrex is the first in a new class of drugs called Cox-2 inhibitors, used to treat the symptoms of rheumatoid arthritis as well as osteoarthritis. IMS HEALTH's regular weekly prescription activity report covering the week ending Mar. 5 becomes available on Monday, March 15. IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries. For the week ending Feb. 26, the majority of physicians dispensing Celebrex continued to be Primary Care Physicians, who wrote 111,592 retail prescriptions representing an increase of 37.9 percent over the previous week. Orthopedic Surgeons and Rheumatologists prescribed the next largest segment of Celebrex prescriptions, dispensing a combined total of 62,458 retail prescriptions, an increase of 38 percent over the previous week's prescribing. IMS HEALTH's weekly prescription tracking service provides comprehensive coverage of three U.S. retail channels -- chain drugstores, independent pharmacies and food stores with pharmacies -- and includes cash and Medicaid prescriptions as well as third-party reimbursement. The service also provides unique access to mail-order prescriptions, making it the most complete market tracking service covering the U.S. pharmaceutical industry. IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries. With more than $1.2 billion in 1998 revenue, IMS HEALTH operates in over 90 countries. IMS HEALTH is the largest pharmaceutical manufacturer information partner, with over 40 years' experience in the industry. Key products and services integral to customer day-to-day operations include: market research for prescription and over-the-counter pharmaceutical products; sales management information to optimize sales force productivity; technology-enabled selling solutions for sales and marketing decision making; and technology systems and information services that support managed care organizations. Additional information and previous press releases are available at the IMS HEALTH website: imshealth.com. nt.excite.com